CoLucid Pharmaceuticals Inc. (CLCD) PT Set at $49.00 by Piper Jaffray Cos.
CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD) received a $49.00 price objective from equities research analysts at Piper Jaffray Cos. in a research report issued on Friday. The firm presently has a an “overweight” rating on the biopharmaceutical company’s stock. Piper Jaffray Cos.’s price target would suggest a potential upside of 28.44% from the company’s previous close.
A number of other equities analysts also recently weighed in on CLCD. Zacks Investment Research downgraded CoLucid Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, June 8th. Ladenburg Thalmann boosted their price objective on CoLucid Pharmaceuticals from $23.00 to $52.00 and gave the stock a “buy” rating in a report on Tuesday, September 6th. Finally, Stifel Nicolaus boosted their price objective on CoLucid Pharmaceuticals from $27.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, September 19th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. CoLucid Pharmaceuticals has an average rating of “Buy” and a consensus price target of $33.05.
CoLucid Pharmaceuticals (NASDAQ:CLCD) traded up 9.82% during midday trading on Friday, reaching $38.15. The company had a trading volume of 768,567 shares. The firm has a 50-day moving average of $19.65 and a 200-day moving average of $10.36. CoLucid Pharmaceuticals has a 12 month low of $3.60 and a 12 month high of $39.05. The stock’s market cap is $584.99 million.
CoLucid Pharmaceuticals (NASDAQ:CLCD) last announced its quarterly earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.84) by $0.22. On average, equities analysts expect that CoLucid Pharmaceuticals will post ($3.91) EPS for the current fiscal year.
In related news, major shareholder Domain Partners Vi, L.P. sold 153,028 shares of the business’s stock in a transaction that occurred on Wednesday, August 3rd. The stock was sold at an average price of $8.45, for a total value of $1,293,086.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder A/S Novo purchased 100,000 shares of the business’s stock in a transaction that occurred on Friday, September 9th. The stock was bought at an average price of $20.00 per share, with a total value of $2,000,000.00. Following the completion of the purchase, the insider now owns 3,156,563 shares of the company’s stock, valued at approximately $63,131,260. The disclosure for this purchase can be found here. 13.70% of the stock is owned by corporate insiders.
Several large investors have recently modified their holdings of the stock. FMR LLC acquired a new stake in CoLucid Pharmaceuticals during the second quarter valued at $554,000. Vanguard Group Inc. boosted its stake in CoLucid Pharmaceuticals by 1.2% in the second quarter. Vanguard Group Inc. now owns 76,242 shares of the biopharmaceutical company’s stock valued at $623,000 after buying an additional 900 shares during the last quarter. Finally, Societe Generale acquired a new stake in CoLucid Pharmaceuticals during the second quarter valued at $464,000. Institutional investors and hedge funds own 30.47% of the company’s stock.
CoLucid Pharmaceuticals Company Profile
CoLucid Pharmaceuticals, Inc is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies.
Receive News & Ratings for CoLucid Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CoLucid Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.